Engaging Patients with Late-Stage Non-Small Cell Lung Cancer in Shared Decision Making about Treatment
- PMID: 34683140
- PMCID: PMC8539978
- DOI: 10.3390/jpm11100998
Engaging Patients with Late-Stage Non-Small Cell Lung Cancer in Shared Decision Making about Treatment
Abstract
Few treatment decision support interventions (DSIs) are available to engage patients diagnosed with late-stage non-small cell lung cancer (NSCLC) in treatment shared decision making (SDM). We designed a novel DSI that includes care plan cards and a companion patient preference clarification tool to assist in shared decision making. The cards answer common patient questions about treatment options (chemotherapy, chemotherapy plus immunotherapy, targeted therapy, immunotherapy, clinical trial participation, and supportive care). The form elicits patient treatment preference. We then conducted interviews with clinicians and patients to obtain feedback on the DSI. We also trained oncology nurse educators to implement the prototype. Finally, we pilot tested the DSI among five patients with NSCLC at the beginning of an office visit scheduled to discuss treatment with an oncologist. Analyses of pilot study baseline and exit survey data showed that DSI use was associated with increased patient awareness of the alternatives' treatment options and benefits/risks. In contrast, patient concern about treatment costs and uncertainty in treatment decision making decreased. All patients expressed a treatment preference. Future randomized controlled trials are needed to assess DSI implementation feasibility and efficacy in clinical care.
Keywords: NSCLC; lung cancer; non-small cell lung cancer; shared-decision making; treatment decision.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Rodríguez-Abreu D., Powell S.F., Hochmair M.J., Gadgeel S., Esteban E., Felip E., Speranza G., De Angelis F., Dómine M., Cheng S.Y., et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: Protocol-specified final analysis from KEYNOTE-189. Ann. Oncol. 2021;32:881–895. doi: 10.1016/j.annonc.2021.04.008. - DOI - PubMed
-
- Reck M., Rodríguez-Abreu D., Robinson A.G., Hui R., Csőszi T., Fülöp A., Gottfried M., Peled N., Tafreshi A., Cuffe S., et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J. Clin. Oncol. 2021;39:2339–2349. doi: 10.1200/JCO.21.00174. - DOI - PMC - PubMed
-
- Ramalingam S.S., Vansteenkiste J., Planchard D., Cho B.C., Gray J.E., Ohe Y., Zhou C., Reungwetwattana T., Cheng Y., Chewaskulyong B., et al. FLAURA Investigators Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N. Engl. J. Med. 2020;382:41–50. doi: 10.1056/NEJMoa1913662. - DOI - PubMed
-
- Zukin M., Barrios C.H., Pereira J.R., Ribeiro R.D.A., de Mendonça Beato C.A., do Nascimento Y.N., Murad A., Franke F.A., Precivale M., de Lima Araujo L.H., et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J. Clin. Oncol. 2013;31:2849–2853. doi: 10.1200/JCO.2012.48.1911. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources